Boundless Bio Inc. (BOLD) Price & Analysis

Compare

31 Followers

BOLD Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.00 - $4.72

Previous CloseN/A

Volume5.57K

Average Volume (3M)204.77K

Market Cap

$26.42M

Enterprise Value-$55.06M

Total Cash (Recent Filing)$127.15M

Total Debt (Recent Filing)$49.51M

Price to Earnings (P/E)―

Beta1.92

Next Earnings

Nov 06, 2025

EPS Estimate

-0.58

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.70

Shares Outstanding22,385,610

10 Day Avg. Volume107,861

30 Day Avg. Volume204,766

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)0.33

Price to Sales (P/S)0.00

P/FCF Ratio-0.78

Enterprise Value/Market Cap-2.08

Enterprise Value/Revenue-52.14

Enterprise Value/Gross Profit1.08K

Enterprise Value/Ebitda0.87

Forecast

1Y Price Target

$4.00

Price Target Upside238.98% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical TrialsAll programs remain on track, with the key proof-of-concept clinical dataset for BBI-355 (CHK1) expected in the second half of 2025.

Financial StabilityThe company reported $138 million in cash and cash equivalents, which they expect to provide runway into 2027.

Future DevelopmentsThe company continues to expect the nomination of a candidate for the novel kinesin program in mid-2025 and the IND submission for the candidate in the first half of 2026.

Bears Say

Clinical Trials SetbackThe shift in development results in a major setback for BOLD's lead program, as the agent returns to proof-of-principle and dose-optimization efforts and novel combination strategies to improve the therapeutic index.

Diagnostic DelaysThe validation of the ecDNA hypothesis with the ECHO diagnostic tool has also been delayed, suggesting the investment thesis may remain in limbo until a new asset, such as the BBI-940, is developed.

Therapeutic ChallengesCombinations of BBI-355 with erlotinib (EGFR) and futibatinib (FGFR) were also not well-tolerated at the Q2D doses required for anti-tumor activity.

Boundless Bio Inc. News

Boundless Bio reports Q2 EPS (70c), consensus (65c)

“We are executing with sharpened focus on programs that we believe have the strongest scientific rationale and greatest...

3d ago

BOLD

Boundless Bio initiated with Early-Stage Biotech at Goldman Sachs

Goldman Sachs analyst Richard Law initiated coverage of Boundless Bio (BOLD) with an Early-Stage Biotech rating, saying the...

15d ago

BOLD

Boundless Bio Reports Q2 2025 Financial Results

Boundless Bio Inc. ( ($BOLD) ) has released its Q2 earnings. Here is a breakdown of the information...

3d ago

BOLD

Boundless Bio Elects Directors and Ratifies Auditor

Boundless Bio Inc. ( ($BOLD) ) just unveiled an update. At the annual meeting of stockholders held on...

2M ago

BOLD

Boundless Bio initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Boundless Bio (BOLD) with a Buy rating and $5 price target Boundless is...

2M ago

BOLD

Boundless Bio Inc. Reports Q1 2025 Financial Results

Boundless Bio Inc. ( ($BOLD) ) has released its Q1 earnings. Here is a breakdown of the information...

2M ago

BOLD

Hold Rating Issued for Boundless Bio Inc. Amid Strategic Setbacks and Delayed Program Validations

In a report released today, Andrew Berens from Leerink Partners downgraded Boundless Bio Inc. (BOLD – Research Report)...

2M ago

BOLD

Boundless Bio downgraded to Market Perform from Outperform at Leerink

Leerink downgraded Boundless Bio (BOLD) to Market Perform from Outperform with a price target of $3, down from...

2M ago

BOLD

Boundless Bio Announces Major Workforce Reduction Strategy

Boundless Bio Inc. ( ($BOLD) ) has shared an update. On May 23, 2025, Boundless Bio announced a...

3M ago

BOLD

Boundless Bio discontinuing BBI-355 and BBI-825 programs

Boundless Bio (BOLD) “provided business updates focused on optimizing the Company’s portfolio for patient impact and long-term value-creation....

3M ago

BOLD

Positive Outlook for Boundless Bio Inc. Driven by Promising Pipeline Developments and Strong Financial Position

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on Boundless Bio Inc. (BOLD – Research Report),...

3M ago

BOLD

Boundless Bio reports Q1 EPS (71c) vs ($12.27) last year

“Boundless remains committed to delivering new therapeutic options to patients with high unmet need oncogene amplified cancers,” said...

3M ago

BOLD

Boundless Bio files $400M mixed securities shelf

16:04 EDT Boundless Bio (BOLD) files $400M mixed securities shelf Published first on TheFly – the ultimate source...

4M ago

BOLD

Boundless Bio’s 2024 Financial Results and Strategic Progress

Boundless Bio Inc. ( ($BOLD) ) has released its Q4 earnings. Here is a breakdown of the information...

4M ago

BOLD

BOLD FAQ

What was Boundless Bio Inc.’s price range in the past 12 months?

Boundless Bio Inc. lowest stock price was $1.00 and its highest was $4.72 in the past 12 months.

What is Boundless Bio Inc.’s market cap?

Boundless Bio Inc.’s market cap is $26.42M.

When is Boundless Bio Inc.’s upcoming earnings report date?

Boundless Bio Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 90 days.

How were Boundless Bio Inc.’s earnings last quarter?

Boundless Bio Inc. released its earnings results on Aug 05, 2025. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.65 by -$0.05.

Is Boundless Bio Inc. overvalued?

According to Wall Street analysts Boundless Bio Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Boundless Bio Inc. pay dividends?

Boundless Bio Inc. does not currently pay dividends.

What is Boundless Bio Inc.’s EPS estimate?

Boundless Bio Inc.’s EPS estimate is -0.58.

How many shares outstanding does Boundless Bio Inc. have?

Boundless Bio Inc. has 22,385,610 shares outstanding.

What happened to Boundless Bio Inc.’s price movement after its last earnings report?

Boundless Bio Inc. reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.65. Following the earnings report the stock price went down -1.667%.

Which hedge fund is a major shareholder of Boundless Bio Inc.?

Currently, no hedge funds are holding shares in BOLD

Boundless Bio Inc. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-42.65%

Trailing 12-Months

Asset Growth

-4.65%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Boundless Bio Inc.

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.

Boundless Bio Inc. (BOLD) Earnings & Revenues

Historic Earnings Reports

BOLD Stock 12 Month Forecast

Average Price Target

$4.00

▲(238.98% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","14":"$14","3.5":"$3.5","10.5":"$10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.5,7,10.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.4276923076923076,1.7253846153846153,2.023076923076923,2.3207692307692307,2.6184615384615384,2.916153846153846,3.213846153846154,3.5115384615384615,3.809230769230769,4.106923076923077,4.404615384615385,4.702307692307692,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.3507692307692307,1.5715384615384616,1.7923076923076922,2.013076923076923,2.233846153846154,2.4546153846153844,2.6753846153846155,2.896153846153846,3.1169230769230767,3.3376923076923077,3.5584615384615383,3.779230769230769,{"y":4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.2738461538461539,1.4176923076923076,1.5615384615384613,1.7053846153846153,1.8492307692307692,1.993076923076923,2.1369230769230767,2.2807692307692307,2.4246153846153846,2.5684615384615386,2.712307692307692,2.856153846153846,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.54,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.54,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.54,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.19,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.41,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >